The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population

• Published in: Cancers Vol. 16; no. 19; p. 3419
• Main Authors: Urru, Silvana A M, Mayer, Flavia, Spila Alegiani, Stefania, Paoloni, Francesca, Guella, Anna, Murru, Roberta, Bucaneve, Giampaolo, Formoso, Giulio, Racanelli, Vito, Ferrarini, Isacco, Fozza, Claudio, Longo, Giuseppe, Musicco, Felice, Campomori, Annalisa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.10.2024; MDPI
• Subjects: Biological products; Biosimilar pharmaceuticals; Chemotherapy; Chronic illnesses; Chronic lymphocytic leukemia; Clinical medicine; Clinical trials; Disease; Drug dosages; Drug therapy; Health care; Hematology; Hospitals; Lymphoma; Monoclonal antibodies; Non-Hodgkin's lymphoma; Non-Hodgkin's lymphomas; Observational studies; Patient outcomes; Patients; Pilot projects; Population studies; Rituximab; Statistics; Survival; Italy; non-Hodgkin lymphoma (NHL); chronic lymphocytic leukemia (CLL); oncohematology; safety; rituximab; biosimilars
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16193419

The clinical safety and efficacy of rituximab biosimilars compared to the reference rituximab (Mabthera) have been well established in randomized trials. However, concerns persist regarding the safety of changing from the reference product to biosimilars, and particularly between different biosimilars. This prospective multicenter observational study was conducted in 13 oncohematology units of eight Italian regions. The study included 800 patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) who received rituximab between March 2018 and June 2022. To minimize survivorship bias, only newly diagnosed patients (i.e., those without prior rituximab treatment) were included in the analysis of adverse drug reactions (ADRs). Thus, this study focused on 505 incident cases (79.8% of the initial cohort) from 13 centers. A total of 3681 rituximab infusions were administered, and 16.8% of the patients experienced at least one ADR. These were observed most frequently during the first infusion (44 patients, 52%) and the second infusion (17 patients, 20%). The most frequent reactions were general disorders and administration site conditions (n. 50, 8% serious). These findings support the clinical safety of rituximab biosimilars and suggest that switching between biosimilars does not increase the risk of adverse events. This evidence may alleviate concerns about biosimilar use, potentially leading to broader acceptance and reduced healthcare costs.